Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Human erythropoietin gene delivery for cardiac remodeling of myocardial infarction in rats.

Lee Y, McGinn AN, Olsen CD, Nam K, Lee M, Shin SK, Kim SW.

J Control Release. 2013 Oct 10;171(1):24-32. doi: 10.1016/j.jconrel.2013.06.022.

2.

Human erythropoietin gene delivery using an arginine-grafted bioreducible polymer system.

Lee Y, Nam HY, Kim J, Lee M, Yockman JW, Shin SK, Kim SW.

Mol Ther. 2012 Jul;20(7):1360-6. doi: 10.1038/mt.2012.62. Erratum in: Mol Ther. 2012 Dec;20(12):2369.

3.

Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells.

Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, Hajjar RJ.

Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H522-9.

4.

Cardioprotective activity of placental growth factor in a rat model of acute myocardial infarction: nanoparticle-based delivery versus direct myocardial injection.

Lu ZX, Mao LL, Lian F, He J, Zhang WT, Dai CY, Xue S, Lu WG, Zhu HS.

BMC Cardiovasc Disord. 2014 Apr 17;14:53. doi: 10.1186/1471-2261-14-53. Retraction in: BMC Cardiovasc Disord. 2015;15:27.

5.

Effects of erythropoietin on cardiac remodeling after myocardial infarction.

Nishiya D, Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S, Iwao H, Takeuchi K, Yoshikawa J, Yoshiyama M.

J Pharmacol Sci. 2006 May;101(1):31-9.

6.

Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats.

Gäbel R, Klopsch C, Furlani D, Yerebakan C, Li W, Ugurlucan M, Ma N, Steinhoff G.

Interact Cardiovasc Thorac Surg. 2009 Jul;9(1):20-5; discussion 25. doi: 10.1510/icvts.2008.191916.

7.

Experimental acute myocardial infarction in rats: HIF-1α, caspase-3, erythropoietin and erythropoietin receptor expression and the cardioprotective effects of two different erythropoietin doses.

Guven Bagla A, Ercan E, Asgun HF, Ickin M, Ercan F, Yavuz O, Bagla S, Kaplan A.

Acta Histochem. 2013 Sep;115(7):658-68. doi: 10.1016/j.acthis.2013.01.005.

PMID:
23453036
8.

Endothelial cells overexpressing IL-8 receptor reduce cardiac remodeling and dysfunction following myocardial infarction.

Zhao X, Zhang W, Xing D, Li P, Fu J, Gong K, Hage FG, Oparil S, Chen YF.

Am J Physiol Heart Circ Physiol. 2013 Aug 15;305(4):H590-8. doi: 10.1152/ajpheart.00571.2012.

9.

Erythropoietin gene delivery using an arginine-grafted bioreducible polymer system.

Nam HY, Lee Y, Lee M, Shin SK, Kim TI, Kim SW, Bull DA.

J Control Release. 2012 Feb 10;157(3):437-44. doi: 10.1016/j.jconrel.2011.10.014.

11.

Angiotensin and bradykinin peptides in rats with myocardial infarction.

Duncan AM, Burrell LM, Kladis A, Campbell DJ.

J Card Fail. 1997 Mar;3(1):41-52.

PMID:
9110254
12.

Impairment of cardiac function and remodeling induced by myocardial infarction in rats are attenuated by the nonpeptide angiotensin-(1-7) analog AVE 0991.

Zeng WT, Chen WY, Leng XY, Tang LL, Sun XT, Li CL, Dai G.

Cardiovasc Ther. 2012 Jun;30(3):152-61. doi: 10.1111/j.1755-5922.2010.00255.x.

PMID:
21167013
13.
14.

Qiliqiangxin improves cardiac function and attenuates cardiac remodeling in rats with experimental myocardial infarction.

Wang J, Zhou J, Ding X, Zhu L, Jiang K, Fu M, Wang S, Hu K, Ge J.

Int J Clin Exp Pathol. 2015 Jun 1;8(6):6596-606.

15.

Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling.

Miki T, Miura T, Yano T, Takahashi A, Sakamoto J, Tanno M, Kobayashi H, Ikeda Y, Nishihara M, Naitoh K, Ohori K, Shimamoto K.

J Pharmacol Exp Ther. 2006 Apr;317(1):68-75.

16.

The inhibition of postinfarct ventricle remodeling without polycythaemia following local sustained intramyocardial delivery of erythropoietin within a supramolecular hydrogel.

Wang T, Jiang XJ, Lin T, Ren S, Li XY, Zhang XZ, Tang QZ.

Biomaterials. 2009 Sep;30(25):4161-7. doi: 10.1016/j.biomaterials.2009.04.033.

PMID:
19539990
17.

Local erythropoietin and endothelial progenitor cells improve regional cardiac function in acute myocardial infarction.

Stein A, Knödler M, Makowski M, Kühnel S, Nekolla S, Keithahn A, Weidl E, Groha P, Schürmann M, Saraste A, Botnar R, Oostendorp RA, Ott I.

BMC Cardiovasc Disord. 2010 Sep 17;10:43. doi: 10.1186/1471-2261-10-43.

18.

Combined therapy with cardioprotective cytokine administration and antiapoptotic gene transfer in postinfarction heart failure.

Okada H, Takemura G, Kosai K, Tsujimoto A, Esaki M, Takahashi T, Nagano S, Kanamori H, Miyata S, Li Y, Ohno T, Maruyama R, Ogino A, Li L, Nakagawa M, Nagashima K, Fujiwara T, Fujiwara H, Minatoguchi S.

Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H616-26. doi: 10.1152/ajpheart.01147.2008.

19.

Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion.

Santos-Gallego CG, Vahl TP, Goliasch G, Picatoste B, Arias T, Ishikawa K, Njerve IU, Sanz J, Narula J, Sengupta PP, Hajjar RJ, Fuster V, Badimon JJ.

Circulation. 2016 Mar 8;133(10):954-66. doi: 10.1161/CIRCULATIONAHA.115.012427.

PMID:
26826180
20.

Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep.

Blom AS, Pilla JJ, Gorman RC 3rd, Gorman JH, Mukherjee R, Spinale FG, Acker MA.

Heart Fail Rev. 2005 Jun;10(2):125-39.

PMID:
16258720
Items per page

Supplemental Content

Support Center